Sistema PJSFC: Sistema Group increases ownership stake in OJSC Sintez

DJ Sistema PJSFC: Sistema Group increases ownership stake in OJSC Sintez

Sistema PJSFC (SSA) 
Sistema PJSFC: Sistema Group increases ownership stake in OJSC Sintez 
31-March-2021 / 10:00 MSK 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Sistema Group increases ownership stake in OJSC Sintez 
31 March 2021, Moscow - Sistema PJSFC ("Sistema", the "Corporation" or, together with its subsidiaries and affiliates, 
the "Group") (LSE: SSA, MOEX: AFKS), announces that its fully owned subsidiary LLC Sistema Telecom Assets has acquired 
32.4% of the share capital of OJSC Sintez, a subsidiary of pharmaceutical holding company Binnopharm Group (controlled 
by Sistema), from JSC National Immunobiological Company ("Nacimbio", controlled by State Corporation RosTec). 
"Increasing our ownership stake in OJSC Sintez is consistent with Sistema's strategy of strengthening our position on 
the pharmaceuticals market and transforming Binnopharm Group into an industry leader. We are continuing to work with 
Nacimbio and RosTec on a number of pharma projects, including production of the Regevac B vaccine for hepatitis B", 
said Sistema President Vladimir Chirakhov. 
"Nacimbio is focusing on developing its biopharma assets with the ultimate aim of marketing fully Russian-made 
state-of-the-art immunobiological products. The sale of an equity interest in OJSC Sintez, which specialises in 
synthetic medicines and medical devices, forms part of this strategy. Since launching the partnership with Sistema, 
Sintez has been ramping up its output of pharmaceutical ingredients, upgrading its production facilities, and improving 
its financial performance. Having found a reliable and efficient partner in Sistema Group, we are happy to continue 
working in tandem in our area of core interest, namely designing and producing state-of-the-art vaccines," said Andrey 
Zagorsky, CEO of Nacimbio. 
Binnopharm Group is a full-cycle Russian pharmaceutical holding company that combines five production sites across 
Russia: JSC Alium (formerly OBL Pharm; Serpukhov district, Moscow region), JSC Binnopharm (two sites at Zelenograd and 
Krasnogorsk), JSC Sintez (Kurgan) and JSC Biocom (Stavropol). Binnopharm Group companies produce a wide range of drugs 
of various therapeutic groups and have the largest portfolio of drugs among Russian manufacturers with more than 450 
marketing authorisations, including the COVID-19 vaccine Sputnik V. Sistema's effective interest in Binnopharm Group 
(jointly owned with VTB) is 79%, with another 15.8% held by an investor consortium that includes the Russia-China 
Investment Fund (co-founded by RDIF and China Investment Corporation) and several major Middle East funds. The 
remaining 5.2% is distributed among individual shareholders. Binnopharm Group owns a 56.2% stake in OJSC Sintez. 
*** 
For further information, please visit www.sistema.ru or contact: 
Public Relations          Investor Relations 
Sergey Kopytov            Nikolai Minashin 
Phone: [phone] Phone: [phone] 
[e-mail]        [e-mail] 

***

Sistema PJSFC is a publicly traded Russian investment company with a diversified portfolio of assets serving over 150 million customers in the sectors of telecommunications, high technology, banking, retail, e-commerce, timber processing, agriculture, real estate, hospitality and healthcare. The company was founded in 1993. Its revenue in 2019 reached RUB 656.9bn, and its total assets as of 31 December 2019 equalled RUB 1.3tn. Sistema's global depositary receipts are listed under the "SSA" ticker on London Stock Exchange. Sistema's ordinary shares are listed under the "AFKS" ticker on Moscow Exchange. Website: www.sistema.com -----------------------------------------------------------------------------------------------------------------------

ISIN:          US48122U2042 
Category Code: MSCM 
TIDM:          SSA 
LEI Code:      213800JSZ2UUK4QQK694 
Sequence No.:  96643 
EQS News ID:   1179835 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------ 
 

(END) Dow Jones Newswires

March 31, 2021 03:00 ET (07:00 GMT)